These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 34518803)

  • 1. Emerging vaccine-breakthrough SARS-CoV-2 variants.
    Wang R; Chen J; Hozumi Y; Yin C; Wei GW
    ArXiv; 2021 Sep; ():. PubMed ID: 34518803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.
    Wang R; Chen J; Hozumi Y; Yin C; Wei GW
    ACS Infect Dis; 2022 Mar; 8(3):546-556. PubMed ID: 35133792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the mechanisms of SARS-CoV-2 evolution and transmission.
    Chen J; Wang R; Wei GW
    ArXiv; 2021 Sep; ():. PubMed ID: 34545334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
    Wang R; Chen J; Gao K; Wei GW
    Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern.
    Pondé RAA
    Virology; 2022 Jul; 572():44-54. PubMed ID: 35580380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
    Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.
    Khan A; Zia T; Suleman M; Khan T; Ali SS; Abbasi AA; Mohammad A; Wei DQ
    J Cell Physiol; 2021 Oct; 236(10):7045-7057. PubMed ID: 33755190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD-A Target for Vaccine Development.
    Gupta D; Kumar M; Sharma P; Mohan T; Prakash A; Kumari R; Kaur P
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease.
    Perez-Gomez R
    J Dev Biol; 2021 Dec; 9(4):. PubMed ID: 34940505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis.
    Kumar R; Srivastava Y; Muthuramalingam P; Singh SK; Verma G; Tiwari S; Tandel N; Beura SK; Panigrahi AR; Maji S; Sharma P; Rai PK; Prajapati DK; Shin H; Tyagi RK
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of the mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America.
    Wang R; Chen J; Wei GW
    ArXiv; 2021 Oct; ():. PubMed ID: 34642638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern.
    Liang Y; Lin H; Zou L; Zhao J; Li B; Wang H; Lu J; Sun J; Yang X; Deng X; Tang S
    Microbiol Spectr; 2021 Dec; 9(3):e0101721. PubMed ID: 34787487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
    Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y
    Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using high-resolution melting analysis.
    Aoki A; Adachi H; Mori Y; Ito M; Sato K; Okuda K; Sakakibara T; Okamoto Y; Jinno H
    J Toxicol Sci; 2021; 46(10):471-476. PubMed ID: 34602531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.